Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

Patent metadata

Field	Value
Publication number	US-9480677-B2
Application number	US-201414510634-A
Country	US
Kind code	B2
Filing date	Oct 9, 2014
Priority date	Jun 29, 2009
Publication date	Nov 1, 2016
Grant date	Nov 1, 2016

Abstract

This invention is directed to the (S)-enantiomer of the compound of formula (I):

or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.

First claim

What is claimed is:

1. A method of treating familial erythromelalgia and primary erythromelalgia in a mammal by the inhibition of ion flux through a voltage-gated sodium channel in the mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of the (S)-enantiomer of 1′-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3′-indol]-2′(1′H)-one having the following formula (I-S):

or a pharmaceutically acceptable solvate or prodrug thereof.

Assignees

• Xenon Pharmaceuticals Inc

Inventors

• Chafeev Mikhail
• Fu Jianmin
• Cadieux Jean-Jacques Alexandre

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title